Bjerre Lise M, Verheij Theo Jm, Kochen Michael M
Department of General Practice/Family Medicine, University of Göttingen, Humboldtallee 38, Göttingen, Germany, D-37073.
Cochrane Database Syst Rev. 2009 Oct 7(4):CD002109. doi: 10.1002/14651858.CD002109.pub3.
Community-acquired pneumonia (CAP), the sixth most common cause of death worldwide, is a common condition representing a significant disease burden for the community, particularly in the elderly. Antibiotics are helpful in treating CAP and are the standard treatment. CAP contributes significantly to antibiotic use, which is associated with the development of bacterial resistance and side-effects. Several studies have been published concerning treatment for CAP. Available data arises mainly hospitalized patients studies. This is an update of our 2004 Cochrane Review.
To summarize current evidence from randomized controlled trials (RCTs) concerning the efficacy of different antibiotic treatments for CAP in participants older than 12.
We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library, 2009, issue 1) which contains the Cochrane Acute Respiratory Infections Group's Specialized Register; MEDLINE (January 1966 to February week 2, 2009), and EMBASE (January 1974 to February 2009).
RCTs in which one or more antibiotics were tested for the treatment of CAP in ambulatory adolescents or adults. Studies testing one or more antibiotics and reporting the diagnostic criteria as well as the clinical outcomes achieved, were considered for inclusion.
Two review authors (LMB, TJMV) independently assessed study reports in the first publication. In this update, LMB performed study selection, which was checked by TJMV and MMK. Study authors were contacted to resolve any ambiguities in the study reports. Data were compiled and analyzed. Differences between review authors were resolved by discussion and consensus.
Six RCTs assessing five antibiotic pairs (1857 participants aged 12 years and older diagnosed with CAP) were included. The study quality was generally good, with some differences in the extent of the reporting. A variety of clinical, radiological and bacteriological diagnostic criteria and outcomes were reported. Overall, there was no significant difference in the efficacy of the various antibiotics.
AUTHORS' CONCLUSIONS: Currently available evidence from RCTs is insufficient to make evidence-based recommendations for the choice of antibiotic to be used for the treatment of CAP in ambulatory patients. Pooling of study data was limited by the very low number of studies assessing the same antibiotic pairs. Individual study results do not reveal significant differences in efficacy between various antibiotics and antibiotic groups. Multi-drug comparisons using similar administration schedules are needed to provide the evidence necessary for practice recommendations.
社区获得性肺炎(CAP)是全球第六大常见死因,是一种常见疾病,给社区带来了重大疾病负担,在老年人中尤为如此。抗生素有助于治疗CAP,是标准治疗方法。CAP在抗生素使用中占很大比例,这与细菌耐药性的产生和副作用有关。已经发表了几项关于CAP治疗的研究。现有数据主要来自住院患者研究。这是我们2004年Cochrane系统评价的更新版。
总结来自随机对照试验(RCT)的当前证据,这些证据涉及12岁以上参与者中不同抗生素治疗CAP的疗效。
我们检索了Cochrane对照试验中心注册库(CENTRAL)(《Cochrane图书馆》,2009年第1期),其中包含Cochrane急性呼吸道感染小组的专业注册库;MEDLINE(1966年1月至2009年2月第2周)和EMBASE(1974年1月至2009年2月)。
对门诊青少年或成人中一种或多种抗生素治疗CAP进行测试的RCT。测试一种或多种抗生素并报告诊断标准以及所取得的临床结果的研究被考虑纳入。
两位综述作者(LMB、TJMV)在首次发表时独立评估研究报告。在本次更新中,LMB进行研究选择,由TJMV和MMK进行检查。与研究作者联系以解决研究报告中的任何歧义。对数据进行整理和分析。综述作者之间的差异通过讨论和达成共识来解决。
纳入了六项评估五对抗生素的RCT(1857名12岁及以上诊断为CAP的参与者)。研究质量总体良好,但报告程度存在一些差异。报告了各种临床、放射学和细菌学诊断标准及结果。总体而言,各种抗生素的疗效没有显著差异。
目前来自RCT的现有证据不足以就门诊患者治疗CAP所用抗生素的选择提出基于证据的建议。由于评估相同抗生素对的研究数量非常少,研究数据的汇总受到限制。个别研究结果未显示各种抗生素和抗生素组之间在疗效上有显著差异。需要使用相似给药方案进行多药物比较,以提供实践建议所需的证据。